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Abstract: To explore the functional consequences of cannabinoid withdrawal in the rat mesolimbic dopamine system,  
we investigated the anatomical morphology of the mesencephalic, presumed dopaminergic, neurons and their main   
post-synaptic target in the Nucleus Accumbens. We found that TH-positive neurons shrink and Golgi-stained medium 
spiny neurons loose dendritic spines in withdrawal rats after chronic cannabinoids administration. Similar results were  
observed after administration of the cannabinoid antagonist rimonabant to drug-naïve rats supporting a role for endocan-
nabinoids in neurogenesis, axonal growth and synaptogenesis. This evidence supports the tenet that withdrawal from  
addictive compounds alters functioning of the mesolimbic system. The data add to a growing body of work which   
indicates a hypodopaminergic state as a distinctive feature of the “addicted brain”. 
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INTRODUCTION 
  Clinical reports described that chronic consumers of even 
low daily doses of cannabis derivatives, experience upon 
cessation of drug administration, overt abstinence signs [1, 
2]. These findings are paralleled by structural and functional 
neuroimaging studies of cannabis use [3]. Likewise, overt 
somatic signs of cannabinoid withdrawal can be elicited in 
experimental models of cannabinoid dependence by adminis-
tering the competitive antagonist of cannabinoid CB1 recep-
tors rimonabant (SR) [4-7], thereby offering the possibility  
to investigate neurobiological effects of cannabinoids in a 
condition that mimics human addictive behaviour [8, 9]. 
  The morphological analysis of neurons [10, 11] has re-
cently seen a widespread increase of the studies concerning 
consequences of long-term administration of drugs [12-15]. 
In fact, these measures are likely to reflect plasticity of active 
synapses and, therefore, synaptic remodelling as a conse-
quence of experience and/or drug-exposure [12]. In this re-
gard, addiction has been conceptualized as one example of 
experience-dependent plasticity whereby experience (i.e. 
long-term exposure to addictive drugs) may affect behav-
ioural, cognitive and psychological functions in a long last-
ing way [12, 16]. 
  Cannabinoid withdrawal produces a marked reduction of 
electrophysiological activity in NAcc-projecting dopamine 
(DA) containing neurons of the rat midbrain [4] and a reduc-
tion of DA outflow in the NAcc shell [17]. This functional 
evidence suggests that cannabinoids withdrawal may struc-
turally alter cellular elements of the mesolimbic system, as it 
was recently shown for opiate dependence [14, 15, 18]. Ac-
cordingly, chronic 
9 TetraHydroCannabinol (THC) treat-
ment has been shown to increase the length of the dendrites 
as well as the number of dendritic branches in both the shell 
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of the NAcc and the medial prefrontal cortex, though not in 
other brain areas [19]. However, since morphological evalua-
tions were made long after drug discontinuation (30 days), it 
is impossible to ascertain the relationship between onset of 
withdrawal and structural changes. 
  Thus, in the present study we investigated the morpho-
logical alterations of Ventral Tegmental area (VTA) and 
Substantia Nigra pars compacta (SNc) DA neurons and their 
accumbal post-synaptic counterparts, the spiny neurons 
(MSN). TH-positive neurons and Golgi-Cox stained MSN 
were evaluated after chronic cannabinoid treatment and 
withdrawal in order to obtain further insights into the mor-
phological features of the mesolimbic DA system and its 
involvement in cannabinoid dependence. In addition, the role 
of endogenous cannabinoids was investigated through ad-
ministration of SR to drug-naïve rats. 
MATERIALS AND METHODS 
  Male Sprague-Dawley albino rats (n=48; Charles River, 
Como, Italy), weighing 200-225 g at the beginning of treat-
ment, were used. Rats were kept on a 12-h light/12-h dark 
cycle with food and water available ad libitum. Experimental 
protocols were approved by the Ethical Committee of the 
University of Sassari and performed in strict accordance with 
the EC regulations for the use of experimental animals (CEE 
N°86/609), and recommended guidelines for the care and use 
of experimental animals approved by the Society for Neuro-
science. Rats were administered twice daily (08:00 a.m. and 
20:00 p.m.), for 6.5 days with either 
9-THC (Sigma, Mi-
lano, Italy) or CP 55,940 (Sigma-Aldrich, Milan, Italy) 
emulsified in 1% Tween 80, then diluted in a saline solution 
and administered i.p. in a volume of 3 ml/Kg. 
  Animals were assigned to the following groups: Chronic 
saline (Sal) (n=6); Chronic THC (15 mg/kg) (THC-C); 24 
hrs spontaneous withdrawal from chronic THC (THC-W); 
precipitated withdrawal from chronic THC (15 mg/kg/ad-
ministration) (THC-SR) (n=6); SR (5 mg/kg) in Sal (SR) Altered Mesolimbic Dopamine System in THC Dependence  Current Neuropharmacology, 2011, Vol. 9, No. 1    201 
(SR) (n=6) (6). On the morning of day 7 rats received the 
first daily administration (vehicle, CP or THC) and 1 hour 
before sacrifice were tested for signs of spontaneous and SR 
precipitated-withdrawal. Animals were anaesthetized with 
urethane (1.3 g/kg  i.p.) before transcardiac perfusion with 
100 ml of ice-cold saline solution immediately followed   
by 400 ml of ice-cold 4% paraformaldehyde. Brains were 
divided into two parts at -2 mm from bregma approximately. 
 The  posterior part of brains, VTA- and SNc-containing, 
was post-fixed for 24 hours in the 4% paraformaldehyde 
solution and cryoprocteted in 30% sucrose in phosphate-
buffered saline (PBS). Coronal sections between -5.80 mm 
and -6.30 mm (25 m thick) from bregma, according to Pax-
inos and Watson [20] were obtained with a cryostat (Micron 
Cryo-Star HM 560, Walldorf, Germany). Sections for TH-
immunolabelling were washed for 3x5 min in PBS, im-
mersed for 30 min in 10% normal goat serum (NGS) in 0.1 
M PBS added with 0.5% Triton X-100 (PBS-TX) and incu-
bated for 2 hours with a mouse monoclonal anti-TH antibody 
(1:500; Chemicon, Temecula, CA, USA) in PBS-TX. Sec-
tions were then washed (3x5min) in PBS-TX and incubated 
with a biotinylated anti-mouse IgG (1:300, Vector Laborato-
ries, Burlingame, CA, USA) in PBS-TX and 1% NGS for 30 
min, rinsed (3x5 min) in PBS-TX and incubated with avidin-
TRITC (1:200, Sigma-Aldrich, Milano, Italy) in PBS-TX 
and 1% NGS overnight at 4°C. All Sections were then 
washed (3x20 min) in PBS-TX and coverslipped with Glyc-
ergel mounting solution (Dako, Milano, Italy). 
  After perfusion, the anterior  part of the brains, NAcc-
containing, were immediately rinsed (15 min x 3 times) in 
0.1 M PBS and immersed in a Golgi-Cox solution. The solu-
tion was changed once after 2 days and the brains were then 
left in fresh Golgi–Cox solution for additional 14 days. After 
this period the brains were cryoprotected with a 30% sucrose 
solution for 2-3 days. 50 m thick coronal slices, beginning 
at 1.70 mm and ending at 0.70 mm from bregma, according 
to Paxinos and Watson [20], were obtained with a cryostat. 
Slices were developed using the procedure described by 
Kolb and McClimans [21]. 
  Leica 4D Confocal Laser Scanning Microscope (CLSM) 
with an argon-krypton laser were used to analyse TH-
positive neurons and Golgi-Cox stained sections. Confocal 
images were generated using 40x oil (na=1.00-0.5) and 100x 
oil (na=1.3). Each frame was acquired eight times and then 
averaged to obtain noise-free images. Optical sections, usu-
ally at consecutive intervals of 0.5 m in Z axis, were im-
aged through the depth of the labelled neurons and saved as 
image stacks as previously described [13, 14]. Maximum 
intensity algorithm was used for 3D recostructions of TH-
immunolabeled cells, while Extended focus algorithm was 
used for 3D recostructions of Golgi-Cox stained neurons 
(Bitplane Imaris V.7). 
  Morphometric analyses were performed by two inde-
pendent observers blind to pharmacological treatments. TH-
immunolabelled somata (80/group) were collected from a 
square area (approx. 200 m/side). When totally included in 
the sections, TH-positive neurons were three-dimensionally 
reconstructed and used for measurements and statistical 
analysis using Bioscan Optimas software (version 6.5.1). 
The cell bodies were manually marked following their pro-
file, excluding all dendritc trunks to measure their area 
(m
2). 
  For each treatment dendritic 80/group segments (at least 
20  m long) of second order dendrites were collected for 
analysis, from 0.7 to 1.70 mm from bregma (58) and identi-
fied by confocal rendered cells. Spines’ density was calcu-
lated by tracing a 10-15 m long “sp” line, along the den-
dritic trunk and counting the number of spines therein. The 
procedure was repeated along the entire dendritic length 
from the bifurcation from the first branch of primary den-
drites to the next bifurcation. 
  Data was processed by a one-way ANOVA followed by 
post-hoc comparisons using the Bonferroni criterion. 
RESULTS 
  Confocal datasets of TH-immunolabeled neurons located 
in the VTA (Fig. 1) and in the dorsomedial portion of SNc 
[22] were morphometrically analysed in order to evaluate the 
 
 
 
 
 
 
 
 
 
Fig. (1). Confocal pictures of representative MSN Golgi stained in Nacc shell (left) and TH-positive neurons in the VTA in saline rats. 202    Current Neuropharmacology, 2011, Vol. 9, No. 1  Spiga et al. 
effects of treatments. Analysis of variance showed anatomi-
cal differences  for mean calculated area (F 639=82.83; 
P<.0001), among experimental groups in the VTA. Post hoc 
analysis revealed that cell bodies in the VTA exhibited 
smaller somata under both THC withdrawals. In particular, a 
mean reduction was found for THC-W (t158= 10.9; 
P<0.0001) and THC-SR (t158= 7.22; P<0.0001), when com-
pared with control. Surprisingly, we also found qualitatively 
similar changes in the SR group (t158= 12.1, P<0.0001) 
whereas no changes were observed in THC-C group (t158= 
0.70, P= 0.48). No statistical differences were found for TH-
positive neurons from SNc (F 639=0.58; P=0.77), (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Percentage (respect of sal group) of mean ± SEM of VTA 
TH-positive neurons areas* indicates p<0.05 vs. sal. 
  One way ANOVA revealed a significant effect in   
the shell  (F  639=107.2; P<.0001), but not in the core   
(F  639=0.58; P=0.77), on spine density in the experimental 
groups (Fig. 3). 
 
Fig. (3). Percentage (respect of sal group) of mean ± SEM of den-
dritic spines densities (number of spines/10 m of second order 
dendrites) of NAcc shell and core MSN. * indicates p<0.05 vs. 
CTRL (student t test post hoc analysis). 
  Post hoc analysis, in the shell, showed a selective reduc-
tion in spine density for spontaneous THC-W (t158= 14.4 
P<0.0001) and pharmacologically precipitated withdrawal 
(THC-SR t158= 12.6 P<0.0001) vs Sal. Interestingly, a reduc-
tion in spine density was also found in the SR group when 
compared to control (t158= 12.2; P<0.0001). Further, post hoc 
analysis failed to reveal any significant difference between 
spine density counts in the shell MSN for THC-C (t158= 1; 
P=0.32) groups vs saline treated rats. 
DISCUSSION 
  The present study shows that withdrawal from a regimen 
of chronic cannabinoid administration profoundly affects the 
morphological characteristics of TH-positive neurons of the 
rat VTA and dendritic spine density of MSN in the NAcc 
shell. In contrast, the area of SNc TH positive neurons, as 
well as core spine density, was unaffected. 
  In particular, spontaneous and SR precipitated with-
drawal from chronic administration of 
9 TetraHydroCan-
nabinol, determined the most significant shrinkage of the 
soma of TH-positive neurons of the VTA. These changes 
were paralleled by a reduction of spine density in the secon-
dary dendrites of accumbal MSN in the shell. In contrast, 
chronic administration of THC does not seem to affect the 
morphology of VTA neurons and spine density in the   
accumbal core MSN, thus pointing to a critical role of   
cannabinoids withdrawal in the shrinkage of mesencephalic 
neurons and spine loss in the NAcc shell. This further 
strengthens the view that withdrawal from chronic cannabinoid 
administration exerts powerful and long lasting [19] changes 
in key brain structures affected by addictive compounds. 
  The synaptic rearrangement  described in the present 
study, is in line with, and significantly extends, previous 
findings [18] and could also be a key factor in the down 
regulation of CB1 receptors after THC-withdrawal [23], as 
well as the CB1-mediated inhibition of excitatory synaptic 
transmission at the excitatory synapses between the prefron-
tal cortex and the NAcc [24]. 
  Interestingly, administration of the CB1 antagonist ri-
monabant in drug naive rats produced effects qualitatively 
similar to those observed in subjects treated with exogenous 
cannabinoids in the areas examined. This unexpected finding 
suggests that endogenous cannabinoids might be involved in 
the trophic control of key elements of the mesolimbic system 
such as VTA DA neurons and their physiological post-
synaptic counterparts (i.e. MSNs). While further experiments 
are needed to corroborate this hypothesis, the present finding 
supports the idea of an endocannabinoid trophic and protec-
tive role [25, 26] at the level of the DA system [27]. Accord-
ingly, endocannabinoids modulate synaptic plasticity in the 
VTA [28] and Substantia Nigra pars reticulata [30]. Alterna-
tively, rimonabant might be acting as an inverse agonist [31, 
32] and, therefore, further experiments will clarify this issue. 
  Irrespective of the mechanisms underlying our observa-
tions, the structural changes occurring at both pre- and post-
synaptic levels are likely to have profound consequences on 
dopaminergic transmission in the shell of the NAcc. Indeed, 
the reduced dopamine firing [5] is accompanied by a 
“shrinkage” of the somatic region, thereby rendering the cell 
more excitable in line with the “size principle” [33]. At the 
post-synaptic side the reduced number of spines, besides the 
obvious loss of connections, would reduce total membrane Altered Mesolimbic Dopamine System in THC Dependence  Current Neuropharmacology, 2011, Vol. 9, No. 1    203 
surface [34, 35], thereby decreasing membrane resistance 
[36], eventually leading to altered excitability. This possibil-
ity would be in line with classical theoretical predictions, and 
subsequent confirmatory experimental tests [36], which as-
cribed to the spine an attenuating effect on synaptic poten-
tials. Importantly, recent studies [37] employing a chronic 
regimen of THC very similar to the one employed here have 
reported that long-term exposure and subsequent withdrawal 
(recordings were performed 24 hours after last treatment) of 
THC, blocks synaptic plasticity in the NAcc and reduces the 
sensitivity of GABAergic and glutamatergic synapses. 
  Dendritic spines are particularly important in synaptic 
plasticity in reason of their rapid changes in volume and/or 
shape in response to stimuli. Is it true that spine number is 
very variable and they can spontaneously appear or disap-
pear, but, what could then be the functional consequence of 
remodelling or losing about 30% of the dendritic spines? 
There are at least two mechanisms directly related to the 
reduction in the number of synapses, which can affect the 
overall firing rate of the neuron. The reduction of neuronal 
membrane associated with the loss of spine increases the 
input resistance of the neuron and, in principle, results in a 
more excitable neuron. On the other hand, the neuron may 
decrease its firing rate because the overall excitatory input is 
reduced. 
  Overall, the present data suggest that the altered architec-
ture of the DA system projecting to the shell of the NAcc 
documented here would profoundly alter the synaptic equi-
librium affecting various neurotransmitters involved in the 
neurobiological mechanisms of cannabis dependence [8, 16]. 
  On the basis of the present and previous findings [14, 15, 
18] we suggest that shrinkage of DA neurons and reduction 
of spine density on their post-synaptic elements (i.e. MSN) 
upon withdrawal from chronic cannabinoid administration 
might represent a morphological correlate of the functional 
deficits detected by electrophysiological [4] and neuro-
chemical [17] means, which may ultimately contribute   
to negative motivational properties of withdrawal from   
addictive drugs [16, 37, 38]. 
  In general, the present data lends further support to the 
notion that drug addiction can be seen as a chronic drug-
induced, aberrant, form of neural plasticity [8, 12, 16, 38], 
whereby DA neurons originating in the VTA represent major 
cellular substrate involved at molecular, cellular [8, 39] and 
behavioral levels [38, 41-43] and is coherent with a recent 
hypothesis [16] underscoring a hypodopaminergic state as a 
distinctive feature of the “addicted brain”. 
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